Several antibody constructs targeting CD20 and the CD3ε subunit, such as mosunetuzumab [9], odronextamab [10] or glofitamab [11,12], have shown promising activity in relapsed or refractory (R/R) lymphomas. Here, MS4A1 is linked to lymphoma.